News

Initial treatment with the drug Soliris (eculizumab) and immunosuppressive therapies was safe and effective for four children with severe atypical hemolytic uremic syndrome (aHUS) who had self-reactive antibodies against the complement factor H (FH). That’s according to a study from Argentina, which reported that all of the children…

Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if an infection with Shiga toxin-producing Escherichia coli (STEC), a trigger of the typical form of the disease, is present and initially upstages the correct diagnosis of aHUS. In a…

The National Organization for Rare Disorders (NORD) is offering patient assistance programs specifically for people in the U.S. with atypical hemolytic uremic syndrome (aHUS), to help cover out-of-pocket medical costs and emergency nonmedical expenses in their daily lives. These initiatives come under NORD’s RareCare program, which was…

Mutations in the Wilms’ tumor 1 (WT1) gene, known to cause a rare kidney disorder called Denys-Drash syndrome, were found in four children who had symptoms of atypical hemolytic uremic syndrome (aHUS), according to recent case series study. “To our knowledge, this is the first report of a series…

The first case of a patient with both atypical hemolytic uremic syndrome (aHUS) and Brugada syndrome, an irregular heartbeat disorder that increases the risk of sudden death, was described in a report involving a 15-year-old girl in Oman. The researchers noted that “atypical HUS is a variable disease that…

Hip surgery triggered atypical hemolytic uremic syndrome (aHUS) in a 49-year-old woman, who was successfully treated with plasma exchange, which is a blood-cleaning procedure, and kidney replacement therapy, according to a case study in India. A prompt diagnosis and multidisciplinary collaboration, as well as early and aggressive treatment of…

This year’s aHUS Awareness Day, Sept. 24, will highlight mental health issues important to people with atypical hemolytic uremic syndrome (aHUS) and their families. The annual event is being organized by the aHUS Alliance, an international umbrella organization that comprises patient groups and aHUS advocates to support patients,…

Soliris (eculizumab), an approved drug for atypical hemolytic uremic syndrome (aHUS), successfully treated a rare case of the disease in a girl, age 14 months, in China, according to a case study. After eight doses of the therapy, the levels of self-reactive antibodies against complement factor H —…

The kidney function of a woman with atypical hemolytic uremic syndrome (aHUS) was completely rescued with Soliris (eculizumab), but only after more than a year of treatment, a case study reports. “This case report supports the hypothesis that kidney pathological [disease] resolution in complement-mediated aHUS requires a long…

A U.S. woman with atypical hemolytic uremic syndrome (aHUS) has been in disease remission for 13 years while receiving treatment with C5 complement inhibitors after undergoing a kidney transplant, a new report details. According to the researchers, this is the longest reported case in the literature of an aHUS…